Tadalafil + Placebo + Alpha1 Blocker

ApprovedCompleted
0 views this week 0 watching Active
Interest: 43/100
43
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Benign Prostatic Hyperplasia

Conditions

Benign Prostatic Hyperplasia

Trial Timeline

Apr 1, 2015 → Feb 1, 2016

About Tadalafil + Placebo + Alpha1 Blocker

Tadalafil + Placebo + Alpha1 Blocker is a approved stage product being developed by Eli Lilly for Benign Prostatic Hyperplasia. The current trial status is completed. This product is registered under clinical trial identifier NCT02431754. Target conditions include Benign Prostatic Hyperplasia.

What happened to similar drugs?

9 of 20 similar drugs in Benign Prostatic Hyperplasia were approved

Approved (9) Terminated (2) Active (9)
Tamsulosin OCASAstellas PharmaApproved
Tamsulosin OCAS + PlaceboAstellas PharmaApproved
Tamsulosin + Finasteride + PlaceboAstellas PharmaApproved
ErtapenemMerckApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02431754ApprovedCompleted

Competing Products

20 competing products in Benign Prostatic Hyperplasia

See all competitors